Marked differences in acute cellular rejection rates between living-donor and deceased-donor liver transplant recipients

Transplantation

Volumn 80, Issue 8, 2005, Pages 1072-1080

  Liu, Lawrence U ^a,b   Bodian, Carol A ^a   Gondolesi, Gabriel E ^a,b   Schwartz, Myron E ^a,b   Emre, Sukru ^a,b   Roayaie, Sasan ^a,b   Schiano, Thomas D ^a,b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Allograft rejection; Clinical transplantation; Liver; Living donor

Indexed keywords

ACUTE CELLULAR REJECTION; ADULT; AGED; ARTICLE; CADAVER DONOR; CONTROLLED STUDY; FEMALE; GENETIC ANALYSIS; GRAFT REJECTION; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER GRAFT; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; RELATIVE; SIBLING;

ACUTE DISEASE; DONOR SELECTION; GRAFT REJECTION; HUMANS; INCIDENCE; LIVER TRANSPLANTATION; LIVING DONORS; TISSUE DONORS;

EID: 27744568321     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000176483.52769.5a     Document Type: Article

References (40)

1. Gridelli B, Remuzzi G. Strategies for making more organs available for transplantation. N Engl J Med 2000; 343: 404,
2. Kim WR, Brown RS, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 227.
3. Emre S, Schwartz ME, Altaca G, et al. Safe use of hepatic allografts from donors older than 70 years. Transplantation 1996; 62: 62.
4. Romero CJ, Gonzalez EM, Ruiz FC, et al. Use of octogenarian livers safely expands the donor pool. Transplantation 1999; 68: 572.
5. Fishbein TM, Fiel MI, Emre S, et al. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 1997; 64: 248.
6. Burton JR, Shaw-Stiffel TA. Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Liver Transpl 2003; 9: 837.
7. Arenas JL, Vargas HE, Rakela J. The use of hepatitis C-infected grafts in liver transplantation. Liver Transpl 2003; 9: 548.
8. Yersiz H, Renz JF, Farmer DG, et al. One hundred in situ split liver transplantations: a single center experience. Ann Surg 2003; 238: 496.
9. Millis JM, Cronin DC, Brady LM, et al. Primary living-donor liver transplantation at the University of Chicago: technical aspects of the first 104 recipients. Ann Surg 2000; 232: 104.
10. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28: 638.
11. Doran TJ, Geczy AF, Painter D, et al. A large, single center investigation of the immunogenetic factors affecting liver transplantation. Transplantation 2000; 69: 1491.
12. Candinas D, Gunson BK, Nightingale P, et al. Sex mismatch as a risk factor for chronic rejection of liver allografts. Lancet 1995; 346: 1117.
13. Brooks BK, Levy MF, Jennings LW, et al. Influence of donor and recipient gender on the outcome of liver transplantation. Transplantation 1996; 62: 1784.
14. Palma F, Jimenez C, Moreno E, et al. Recipient factors as determinants of mortality after adult liver transplantation. World J Surg 1999; 23: 1282.
15. Sheiner PA, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30.
16. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5: S107.
17. Sheiner PA, Magliocca JF, Bodian CA, et al. Long-term medical complications in patients surviving ≥5 years after liver transplant. Transplantation 2000; 69: 781.
18. Haagsma EB, Hagens VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001; 34: 84.
19. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222.
20. Trotter JF, Wachs M, Everson GT, Kam I. Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Eng J Med 2002; 346: 1074.
21. Russo MW, Brown RS. Adult living donor liver transplantation. Am J Transplant 2004; 4: 458.
22. Drews D, Sturm E, Latta A, et al. Complications following living-related and cadaveric liver transplantation in 100 children. Transplant Proc 1997; 29: 421.
23. Eid B, Villard F, Stamm D, et al. Review of living related versus cadaveric donors in pediatric liver transplantation: the Lyon experience. Transplant Proc 2000; 32: 453.
24. Reding R, de Goyet JD, Delbeke I, et al. Pediatric liver transplantation with cadaveric or living related donors: comparative results in 90 elective recipients of primary grafts. J Pediatr 1999; 134: 280.
25. Minamiguchi S, Sakurai T, Fujita S, et al. Living related liver transplantation: histopathologic analysis of graft dysfunction in 304 patients. Human Path 1999; 30: 1479.
26. Matas AJ, Payne WD, Sutherland DER, et al. 2500 living donor kidney transplants: a single-center experience. Ann Surg 2001; 234: 149.
27. Wiland AM, Fink JC, Weir MR, et al. Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. Transplantation 2004; 77: 422.
28. Campbell SB, Hothersall E, Preston J, et al. Frequency and severity of acute rejection in live- versus cadaveric-donor renal transplants. Transplantation 2003; 1452.
29. Miller CM, Gondolesi GE, Florman S, et al. 109 living donor liver transplants in adults and children. A single center experience. Ann Surg 2001; 234: 301.
30. Demetris AJ, Batts KP, Dhillon AP, et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658.
31. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. Springer: New York, 1997.
32. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 1993; 12: 737.
33. SAS/Stat User's Guide, Version 8, Gary NC: SAS Institute Inc, 1999.
34. Charco R, Vargas V, Balsells J, et al. Influence of anti-HLA antibodies and positive T-lymphocytotoxic crossmatch on survival and graft rejection in human liver transplantation. J Hepatol 1996; 24: 452.
35. Schiano TD, Kim-Schluger L, Gondolesi G, Miller CM. Adult living-donor liver transplantation: the hepatologist's perspective. Hepatology 2001; 33: 3.
36. Janssen W, Koo DD, Cerundolo L, et al. Cadaveric versus living-donor livers: differences in inflammatory markers after transplantation. Transplantation 2003; 76: 1599.
37. Marcos A, Fisher RA, Ham JM, et al. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000; 69: 2410.
38. Taber DJ, Dupuis RE, Fann AL, et al. Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients. Liver Transpl 2002; 8: 219.
39. Liu LU, Schiano TD, Min AD, et al. Syngeneic living-donor liver transplantation without the use of immunosuppression. Gastroenterology 2002; 123: 1341.
40. Bartlett AS, Ramadas R, Fumess S, et al. The natural history of acute histologic rejection without biochemical graft dysfunction in orthotopic liver transplantation: a systemic review. Liver Transpl 2002; 12: 1147.